Bayer announced the submission of marketing authorization applications to the FDA and to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), seeking approval… read more.
Bayer announced that new analyses from the Phase III FINEARTS-HF trial evaluating finerenone (Kerendia) in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of… read more.
A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines, according… read more.
Researchers from the SUMMIT trial have reported that treatment with tirzepatide has reduced the risk of worsening heart failure and cardiovascular disease-related death for obese adults. The findings… read more.
Alnylam Pharmaceuticals, the leading RNAi therapeutics company, today announced that the Company will present data from its transthyretin amyloidosis (ATTR) and hypertension programs at the upcoming American Heart Association (AHA)… read more.
Abbott announced a new, first-of-its-kind clinical trial designed to improve outcomes in patients with worsening heart failure who could benefit from advanced therapy options. The TEAM-HF trial, which… read more.
Detailed results from the Phase III study FINEARTS-HF demonstrate that compared to placebo, finerenone (Kerendia/ Firialta) showed a statistically significant improvement in cardiovascular outcomes in patients with heart… read more.
Compared to placebo-treated patients with heart failure and mildly reduced or preserved ejection fraction, similar patients treated with finerone have achieved a significantly lower rate of a composite… read more.
Abbott announced that the FDA has approved a change to its label that will help patients who receive a HeartMate 3 left ventricular assist device (LVAD, or heart… read more.
scPharmaceuticals Inc. announced that the FDA has approved its Supplemental New Drug Application (sNDA) seeking to expand the Furoscix indication for heart failure patients. At approval, Furoscix was… read more.
A new small study led by Johns Hopkins Medicine researchers and published July 25th in the journal Nature Cardiovascular Research has revealed the impact of obesity on muscle structure in patients having a… read more.
UVA Health researchers have developed a powerful new risk assessment tool for predicting outcomes in heart failure patients. The researchers have made the tool publicly available for free… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
